HomeCompareEMKR vs PFE

EMKR vs PFE: Dividend Comparison 2026

EMKR yields 64.62% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMKR wins by $765.5K in total portfolio value
10 years
EMKR
EMKR
● Live price
64.62%
Share price
$3.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$815.1K
Annual income
$201,544.69
Full EMKR calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — EMKR vs PFE

📍 EMKR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMKRPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMKR + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMKR pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMKR
Annual income on $10K today (after 15% tax)
$5,492.73/yr
After 10yr DRIP, annual income (after tax)
$171,312.99/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, EMKR beats the other by $148,993.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMKR + PFE for your $10,000?

EMKR: 50%PFE: 50%
100% PFE50/50100% EMKR
Portfolio after 10yr
$432.3K
Annual income
$113,901.70/yr
Blended yield
26.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

EMKR
Analyst Ratings
8
Buy
3
Hold
Consensus: Buy
Price Target
$2.50
-19.2% upside vs current
Range: $2.00 — $3.00
Altman Z
-10.6
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMKR buys
0
PFE buys
0
No recent congressional trades found for EMKR or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMKRPFE
Forward yield64.62%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$815.1K$49.6K
Annual income after 10y$201,544.69$26,258.71
Total dividends collected$685.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$2.50$27.50

Year-by-year: EMKR vs PFE ($10,000, DRIP)

YearEMKR PortfolioEMKR Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$17,162$6,462.04$9,153$693.39+$8.0KEMKR
2$28,728$10,364.64$8,593$849.25+$20.1KEMKR
3$46,954$16,214.65$8,336$1,066.78+$38.6KEMKR
4$75,008$24,767.79$8,437$1,384.80+$66.6KEMKR
5$117,237$36,977.95$9,013$1,875.40+$108.2KEMKR
6$179,458$54,014.95$10,306$2,680.72+$169.2KEMKR
7$269,294$77,273.40$12,820$4,101.38+$256.5KEMKR
8$396,514$108,370.00$17,673$6,826.70+$378.8KEMKR
9$573,398$149,127.56$27,543$12,591.86+$545.9KEMKR
10$815,080$201,544.69$49,560$26,258.71+$765.5KEMKR

EMKR vs PFE: Complete Analysis 2026

EMKRStock

EMCORE Corporation, together with its subsidiaries, provides advanced mixed-signal optics products in the United States, Canada, Asia, Europe, and internationally. It operates in two segments, Aerospace and Defense, and Broadband. The company offers navigation system and inertial sensing products, such as fiber optic gyros products that includes gyroscopes, inertial measurement units (IMU), and inertial navigation systems (INS), as well as QMEMS gyroscopes, accelerometers, IMUs, and INS products primarily for the aerospace and defense markets; and defense optoelectronics comprising optiva platform fiber optic transport systems and erbium doped fiber amplifiers, as well as ruggedized microwave flange-mount transmitters, receivers, and optical delay line products. It also provides cable TV (CATV) lasers and transmitters that are used in forward-and return-path broadband, subassembly components, analog fiber-optic transmitters, quadrature amplitude modulation transmitters, and CATV fiber amplifiers. In addition, the company offers high-power gain chips products, photodiode products, and GPON fiber-to-the-premises (FTTP) and data center chip products for the telecommunication markets; and lasers, receivers, and photodetector components for wireless, distributed sensing, and light detecting and ranging applications. It serves CATV, optical sensing, telecom, data center, and navigation and defense optoelectronics markets. The company sells its products through direct sales force, application engineers, third party sales representatives, and distributors. EMCORE Corporation was founded in 1984 and is headquartered in Alhambra, California.

Full EMKR Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this EMKR vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMKR vs SCHDEMKR vs JEPIEMKR vs OEMKR vs KOEMKR vs MAINEMKR vs JNJEMKR vs MRKEMKR vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.